Adamas Pharmaceuticals Inc (ADMS) Shares Sold by TIAA CREF Investment Management LLC

TIAA CREF Investment Management LLC lessened its holdings in Adamas Pharmaceuticals Inc (NASDAQ:ADMS) by 8.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 42,256 shares of the specialty pharmaceutical company’s stock after selling 3,718 shares during the quarter. TIAA CREF Investment Management LLC owned 0.15% of Adamas Pharmaceuticals worth $846,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ADMS. Macquarie Group Ltd. boosted its holdings in shares of Adamas Pharmaceuticals by 36.2% in the 3rd quarter. Macquarie Group Ltd. now owns 1,785,118 shares of the specialty pharmaceutical company’s stock valued at $35,738,000 after purchasing an additional 474,808 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Adamas Pharmaceuticals by 24.3% in the 2nd quarter. BlackRock Inc. now owns 1,846,096 shares of the specialty pharmaceutical company’s stock valued at $47,684,000 after acquiring an additional 361,303 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Adamas Pharmaceuticals in the 3rd quarter valued at $4,316,000. Point72 Asset Management L.P. lifted its stake in shares of Adamas Pharmaceuticals by 7.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,443,700 shares of the specialty pharmaceutical company’s stock valued at $48,923,000 after acquiring an additional 171,585 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in shares of Adamas Pharmaceuticals by 18.1% in the 3rd quarter. Alliancebernstein L.P. now owns 846,379 shares of the specialty pharmaceutical company’s stock valued at $16,945,000 after acquiring an additional 129,763 shares during the last quarter. 88.26% of the stock is currently owned by hedge funds and other institutional investors.

Get Adamas Pharmaceuticals alerts:

Shares of NASDAQ:ADMS opened at $9.08 on Wednesday. The firm has a market cap of $247.94 million, a P/E ratio of -2.29 and a beta of 1.41. The company has a debt-to-equity ratio of 1.01, a current ratio of 8.95 and a quick ratio of 8.74. Adamas Pharmaceuticals Inc has a 12-month low of $7.42 and a 12-month high of $35.62.

A number of research analysts have recently commented on ADMS shares. HC Wainwright set a $40.00 price target on Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, January 14th. Mizuho reiterated a “hold” rating and issued a $11.00 price target on shares of Adamas Pharmaceuticals in a research note on Friday, January 11th. Cowen set a $30.00 price target on Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 1st. ValuEngine cut Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 2nd. Finally, Leerink Swann started coverage on Adamas Pharmaceuticals in a research note on Monday, November 12th. They issued an “outperform” rating and a $20.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $31.25.

TRADEMARK VIOLATION WARNING: “Adamas Pharmaceuticals Inc (ADMS) Shares Sold by TIAA CREF Investment Management LLC” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2019/02/13/adamas-pharmaceuticals-inc-adms-shares-sold-by-tiaa-cref-investment-management-llc.html.

Adamas Pharmaceuticals Profile

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Featured Article: Why investors pay attention to retained earnings

Want to see what other hedge funds are holding ADMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adamas Pharmaceuticals Inc (NASDAQ:ADMS).

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.